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INTRODUCTION
The true prevalence of hypertrophic cardiomyopathy (HCM) in childhood is unknown,
but population-based studies have reported an annual incidence between 0.24–0.47
per 100,000 children1–3. The aetiology of disease is more heterogeneous than that seen
in adult populations, with up to 30% of patients having an inborn error of metabolism,
malformation syndrome or neuromuscular syndrome4,5. However, as in adults, most
cases are caused by mutations in the cardiac sarcomere protein genes, even in young
children6,7. The long-term outcome of childhood HCM is highly variable and has been
shown to depend partly on the age of presentation and underlying aetiology4,8,9. Outside
of infancy, the most frequent cause of mortality is sudden cardiac death (SCD), and one
of the greatest challenges in managing young patients with HCM is identifying those at
greatest risk of an arrhythmic event.
HCM has been reported as the most common cause of SCD in young athletes10, but
published estimates of the rate of SCD in childhood HCM have varied widely. Initial
reports from small, highly selected populations suggested a very high mortality
secondary to SCD, with reported rates of up to 7% per year11. Yet, reflecting what has
been seen in adult practice, the reported SCD rates have fallen over time. The most
recent population-based studies report an annual SCD rate of 1–2% per year5,8, which,
although lower than previously thought, is still higher than the SCD rates reported in
adults. There is therefore a subset of children who would benefit from preventative
implantable cardioverter defibrillator (ICD) therapy. ICDs have been shown to be effective
at terminating malignant arrhythmias in childhood HCM, but these young patients
experience a higher rate of complications compared to adults. There is a need to robustly
identify those patients who are most likely to benefit from this intervention.
RISK FACTORS FOR SCD IN CHILDHOOD HCM
Risk factors for SCD in adult HCM include prior ventricular fibrillation (VF) or sustained
ventricular tachycardia (VT); family history of sudden cardiac death; unexplained
syncope; non-sustained ventricular tachycardia (NSVT); maximal left ventricular wall
thickness >30 mm; left atrial dilatation; and left ventricular outflow tract obstruction.
These conventional clinical risk factors are used for risk stratification of SCD in adult
patients.
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Table 1 Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy. Adapted
from Norrish et al.
‘Major’ clinical risk factora Hazard ratio (95% confidence interval)
Previous aborted cardiac event 5.4 (3.67–7.95), p< 0.001
Non-sustained ventricular tachycardia 2.13 (1.21–3.74), p= 0.009
Unexplained syncope 1.89 (0.69–5.16), p= 0.22
Extreme left ventricular hypertrophyb 1.8 (0.75–4.32), p= 0.19
‘Minor’ risk factorc
Left atrial diameter, Family history SCD, Gender, Age, Symptoms, ECG changes, Abnormal
blood pressure response to exercise, LVOTO
Notes.
a‘Major’ risk factor defined as being investigated in at least 4 studies and significantly associated with SCD in   2 statistical
analysis.
bMaximum LV thickness >30mm, or Z-score >6.
c‘Minor’ risk factor defined as being associated with SCD in 1 analysis.
Although a number of potential risk factors for SCD in childhood HCM have been
reported in the literature over the past 30 years, the lack of consistent definitions
and well-designed, large population studies means that the evidence for individual
risk factors is not robust. A recent systematic review and meta-analysis of clinical risk
factors for SCD in childhood HCM12 identified twenty-five studies which explored the role
of twenty- three separate clinical risk factors. The majority of studies were retrospective,
small (all but 3 studies had less than 150 participants) and described heterogeneous
populations. Four clinical risk factors were identified as being ‘major risk factors’
and likely to be associated with SCD in childhood HCM (Table 1): previous aborted
cardiac arrest or sustained VT; unexplained syncope; NSVT; and extreme left ventricular
hypertrophy. Left atrial diameter did not meet the major risk factor criteria, but was
associated with SCD in two out of three studies. ‘Minor risk factors’ included a family
history of SCD, gender, age, symptoms, electrocardiograph findings, blood pressure
response to exercise and left ventricular outflow tract obstruction. The evidence for the
role of individual clinical risk factors is summarised below and in Table 2.
Previous adverse cardiac event
A history of a previous aborted cardiac arrest due to VT or VF, or sustained VT causing
haemodynamic compromise is recognised to be a risk factor for SCD in childhood HCM,
with a hazard ratio of 5.4 (95% CI [3.68–7.95], p< 0.001)12–17(Figure 1). In recognition
of this, both the European and North American guidelines recommend the implantation
of an ICD for secondary prevention if there has been a previous adverse event18,19
(Figure 5).
Unexplained syncope
Syncope that is unexplained after investigation has been evaluated in several
studies13,15–17,20,21 and shown to be associated with an increased with of SCD in
childhood HCM. The reported hazard ratio is 1.89 (95% CI [0.69–5.16], p= 0.22) and
odds ratio estimate is 2.64 (96% CI [1.21–5.79], p= 0.02) (Figure 2). In adults with HCM,
syncope occurring within the last 6 months may be more predictive of SCD compared to
a more distant syncopal event; the importance of timing of syncopal events has not been
explored in childhood HCM.
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Table 2 Summary of evidence for ‘Minor’ risk factors for sudden cardiac death in childhood
hypertrophic cardiomyopathy.
Clinical risk factors Summary of evidence
Gender No studies have reported a significant association between SCD
and gender
Age Presentation in infancy is associated with an increased risk of
mortality secondary to congestive cardiac failure5,8. Outside
infancy the majority of studies found no association with age and
risk of SCD.
Symptoms A wide range of symptoms can be seen in childhood HCM and
the role of symptoms in risk stratification for SCD has not been
systematically assessed.
Family history of SCD Only 1 paediatric study has reported a significant association with
SCD15.
ECG changes QTc dispersion has been reported to be associated with SCD in 2
studies13,17.
Other ECG parameters that have been analysed include RS sum23
and heart rate variability31,32.
Abnormal BP response to
exercise
No studies have reported a significant association with SCD
Left atrial enlargement Increased left atrial size was associated with an increased risk of
SCD in two studies17,24,25
Left ventricular outflow tract
obstruction
Only 1 paediatric study reported an increased risk of SCD with
increasing LVOT gradient17. A gradient above 30mmHg was not
predictive of SCD in this study.
Restrictive physiology Echocardiographic markers for restrictive physiology may increase
the risk for SCD17,24,25
Late Gadolinium enhancement
(LGE) on cardiac Magnetic Reso-
nance
The presence of LGE has been shown to be associated with
increased LV wall thickness/mass33,34. An independent role for LGE
in predicting SCD in childhood HCM has not been show.
Figure 1. a) Hazard ratios for sudden cardiac death or cardiovascular death for previous adverse
event. The size of the square corresponds with the number of patients in the study. The bars represent
the upper and lower 95% CI. Hazard ratios with CI >1 indicate a significant association with sudden
cardiac death. b) Odds ratios for sudden cardiac death or cardiovascular death for previous adverse
event. The size of the square corresponds with the number of patients in the study. The bars represent
the upper and lower 95% CI. Odds ratios with CI >1 indicate a significant association with sudden cardiac
death. Reproduced from Norrish et al.12
Page 4 of 8
Norrish & Kaski. GCSP 2018:24
Figure 2. a) Hazard ratios for sudden cardiac death or cardiovascular death for unexplained syncope. b)
Odds ratio for sudden cardiac death or cardiovascular death for unexplained syncope. Reproduced from
Norrish et al. 12.
Figure 3. a) Hazard ratios for sudden cardiac death or cardiovascular death for non-sustained VT. b)
Odds ratio for sudden cardiac death or cardiovascular death for non-sustained VT. Reproduced from
Norrish et al.12
NSVT
Non-sustained ventricular tachycardia (NSVT) is defined as three or more consecutive
ventricular beats occurring at a rate of greater than 120 beats/min with a duration of
less than 30 seconds on ambulatory ECG recordings18. The prevalence of NSVT during
ambulatory ECG monitoring in childhood HCM is unknown, but it has been shown to be
an independent predictor of SCD in childhood HCM with a combined hazard ratio of 2.13
(95% CI [1.21–3.74], p= 0.0009) (Figure 3)13,14,16,17,21,22.
Maximum left ventricular wall thickness
The association between SCD and severity or extent of left ventricular hypertrophy (LVH)
has been investigated in multiple studies4,13–17,21–23, several of which have reported a
significant association16,21,23 (Figure 4). However, there is significant variability in the
measurement of LVH. There is currently no consensus on the most clinically important
measure of LVH for risk stratification. The ESC guidelines include severe LVH (maximum
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Figure 4. a) Hazard ratios for sudden cardiac death or cardiovascular death for extreme LVH. b) Odds
ratio for sudden cardiac death or cardiovascular death for extreme LVH. Reproduced from Norrish et al.12
Figure 5. European Society of Cardiology recommendations for implantation of cardioverter
defibrillators in children. *Major paediatric risk factors: Maximum left ventricular wall thickness
 30mmor a Z-score  6, unexplained syncope, non-sustained ventricular tachycardia ( 3 consecutive
ventricular beats at  120 BPM lasting, 30 seconds), family history of SCD (one or more first-degree
relatives with SCD aged, 40 years with or without the diagnosis of HCM, or SCD in a first-degree relative at
any age with an established diagnosis of HCM).
LV wall thickness  30 mm or Z-score  6) as a risk factor for SCD, but, importantly, only 1
study has shown a significantly increased risk of SCD using this definition.
Family history of SCD
A family history of SCD is defined as the sudden death of a first-degree relative <40 years
of age with or without a known diagnosis of HCM, or SCD in a first-degree relative at any
age with an established diagnosis of HCM18. It is included as a risk factor for SCD in the
ESC guidelines, but, despite multiple studies investigating this risk factor4,13–16,22, only
one paediatric study has reported a significant association15. This is in contrast to adult
practice, where multiple studies have shown an increased risk of SCD in the presence
of a family history. Possible explanations for this difference include a higher prevalence
of de novomutations in childhood HCM, a lower proportion of sarcomeric disease and
insufficient reporting of family history in published studies.
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Left ventricular outflow tract obstruction
LVOT obstruction is conventionally accepted as a risk factor for SCD in adult HCM, but,
although it has been evaluated in several paediatric studies8,13,14,17,22, only one reported
an increased risk of SCD with increasing LVOT gradient17. A gradient above 30mmHg was
not predictive of SCD in this study.
Left atrial enlargement
Increased left atrial size was associated with an increased risk of SCD in two studies17,24,25
and is likely to be important for risk stratification in childhood HCM.
Abnormal blood pressure response to exercise
An abnormal blood pressure response to exercise (ABPRE) is defined as the failure of
systolic blood pressure (BP) to rise by   20mmHg (flat blood pressure response) or a fall
in blood pressure during exercise (hypotensive blood pressure response). Patients <40
years with an ABPRE have been reported to have a higher risk of SCD26, but no significant
association has been found in paediatric studies14–17.
Current approach to risk stratification in childhood HCM
Not surprisingly, given the sparsity of evidence, the current European and American
guidelines18,19 contain only short sections on risk stratification for SCD in childhood
HCM. Both guidelines recommend the use of four clinical risk factors to predict SCD
(maximum LV wall thickness   30 mm or Z score  6; unexplained syncope; NSVT; or
family history of SCD). The European guidelines recommend the implantation of an ICD
for primary prevention in those with two or more risk factors18, whilst the North American
guidelines state an ICD should be considered in the presence of a single risk factor19
(Figure 1). As discussed above, the evidence supporting the use of some of these risk
factors to predict SCD in childhood HCM is not robust. Aside from the clinical risk factors
chosen, this approach to risk stratification provides relative rather than absolute risks
for non-homogeneous groups, and necessarily uses binary cut-offs for the purpose of
risk stratification, the clinical validity of which may be questioned. Moreover, the simple
summation of risk factors in adult HCM has been shown to have a low predictive power
for SCD, leading to unnecessary ICD implantation in some patients27. This is a particular
concern for young patients who are at increased risk of complications from ICD.
To overcome some of these limitations, the European Society of Cardiology has
more recently endorsed the use of a SCD risk-prediction model (HCM Risk-SCD)18,28
for adults with HCM. This model provides an individualised estimate for 5-year SCD
risk utilising clinical predictor variables associated with SCD in multivariable analyses.
Independent, external comparison of these two approaches has shown that the HCM-
risk SCD model improves the risk stratification of adult patients with HCM29,30. However,
this model is currently not validated for patients use in patients under the age of 16
years, and although it can be used for patients aged 16-18, years, this group of young
people constituted a small proportion of the development cohort (n=82/3675, 2%) and
so further evaluation of their risk may be needed.
Future of risk stratification in childhood HCM
Risk stratification for SCD in adults and children with HCM remains a significant
challenge. Our current understanding of the conventional risk factors for SCD in
childhood is limited by the lack of consistent definitions and well-designed, large
population studies. Moreover, the role of novel potential risk factors for SCD including
genetics and advanced imaging techniques have not yet been systematically evaluated.
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However, risk stratification for patients presenting at a young age has additional
challenges due to the heterogeneity of the patient cohort (including age of presentation,
symptoms and underlying aetiology) and the effect of somatic growth, which means that
a patient’s phenotype may evolve considerably during childhood, with possible important
implications for risk stratification.
As childhood HCM is a rare disease and SCD is a rare outcome, the challenge of
improving risk stratification in childhood HCM can only be addressed through multi-
centre, large-scale, collaborative projects. In response to this, we have established an
International Paediatric Hypertrophic Cardiomyopathy Consortium consisting of 38
cardiac centres worldwide caring for paediatric patients with HCM. A cohort of over
1400 patients has been created which will allow for the systematic evaluation of the
role of individual risk factors for SCD in childhood HCM with the aim of improving risk
stratification for these patients.
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